Bone Marrow Transplant (HSCT) in Turkey
Haematopoietic stem cell transplantation (HSCT) in Turkey offers patients with blood cancers and bone marrow disorders access to world-class allogeneic and autologous transplant programmes at a fraction of Western costs.
What is Bone Marrow Transplant (HSCT)?
Haematopoietic stem cell transplantation (HSCT) — commonly known as a bone marrow transplant — is a procedure in which a patient's diseased or damaged blood-forming stem cells are replaced with healthy stem cells. These stem cells, which reside primarily in the bone marrow, are responsible for producing all blood cells: red cells, white cells, and platelets. HSCT can be either autologous (using the patient's own previously collected and stored stem cells) or allogeneic (using stem cells from a matched donor — a sibling, parent, or unrelated matched donor from a registry). Turkey has built highly specialised HSCT programmes at leading haematology centres in Istanbul and Ankara, offering international patients access to both transplant types with strong clinical outcomes.
Unlike solid organ transplantation, allogeneic HSCT does not require the same family-only restriction under Turkish transplant law, as stem cell registries (including the Turkish national registry and international registries such as DKMS and NMDP) can be searched for unrelated matched donors when no suitable family match exists.
How is it Performed?
The HSCT process unfolds across several distinct phases. First, a conditioning regimen of high-dose chemotherapy (with or without total body irradiation) is administered over 5–10 days to destroy the patient's existing diseased marrow and suppress the immune system to prevent rejection of the incoming stem cells. Stem cells are then infused intravenously — a process resembling a blood transfusion — on "Day 0." In allogeneic transplants, the donor may undergo bone marrow harvest under general anaesthesia or, more commonly today, peripheral blood stem cell collection via apheresis after stimulation with G-CSF injections over 4–5 days. Engraftment — the process by which the new stem cells establish themselves in the bone marrow and begin producing blood cells — typically occurs within 10–21 days after infusion.
Who is a Candidate?
HSCT is indicated for a range of haematological conditions. Autologous HSCT is used primarily for multiple myeloma, relapsed Hodgkin lymphoma, and non-Hodgkin lymphoma. Allogeneic HSCT is used for acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), myelodysplastic syndrome (MDS), aplastic anaemia, thalassaemia major, sickle cell disease, and certain immune deficiency disorders. Candidacy depends on disease stage, patient age and fitness (performance status), organ function, and donor availability. A comprehensive pre-transplant work-up includes disease staging, cardiac and pulmonary function tests, infectious disease screening, and HLA typing for allogeneic candidates.
Recovery & Aftercare
The early post-transplant period (days 0–30) is the most medically intensive. Patients are managed in a specialised haematology unit or bone marrow transplant ward with HEPA-filtered air, strict infection control, and close monitoring of blood counts. Transfusion support is common before engraftment. The primary early risks are febrile neutropenia (dangerous infections during the period of very low white cell count) and, in allogeneic transplants, graft-versus-host disease (GvHD), in which donor immune cells attack host tissues — managed with prophylactic immunosuppression. Most patients are hospitalised for 4–6 weeks from the start of conditioning. After discharge, frequent outpatient monitoring continues for several months. International patients should plan to remain in Istanbul for at least 60–90 days from the start of conditioning before it is medically appropriate to travel home.
Why Turkey & Turkare?
Turkish haematology centres have invested heavily in HSCT infrastructure over the past decade, with dedicated bone marrow transplant units, experienced haematologists, and access to both national and international stem cell registries. The total cost of HSCT in Turkey — covering conditioning chemotherapy, the transplant procedure, hospitalisation, and early follow-up — is substantially lower than in the United States, Germany, or the United Kingdom. Autologous HSCT in Turkey typically costs $40,000–$60,000, while allogeneic HSCT from a matched related or unrelated donor ranges from $60,000–$80,000. Turkare identifies the most appropriate transplant centre for your specific diagnosis, coordinates donor search if required, assists with long-stay accommodation and interpreter services, and ensures a detailed handover to your haematologist at home.
Frequently asked questions
What is the difference between autologous and allogeneic bone marrow transplant?
In an autologous transplant, the patient's own stem cells are collected before high-dose chemotherapy, frozen and stored, then reinfused after the conditioning regimen. Because the cells are the patient's own, there is no risk of rejection or graft-versus-host disease (GvHD). Autologous transplants are used mainly for multiple myeloma and lymphomas. In an allogeneic transplant, stem cells come from a matched donor — ideally a sibling with a full HLA match, though matched unrelated donors found through registries are also used. Allogeneic transplants carry risks of GvHD and rejection but offer the potential "graft-versus-leukaemia" effect — where donor immune cells actively destroy residual cancer cells — making them the preferred approach for leukaemia and myelodysplastic syndrome.
How much does a bone marrow transplant cost in Turkey compared to other countries?
Autologous HSCT in Turkey costs approximately $40,000–$60,000 all-inclusive, covering stem cell collection, conditioning chemotherapy, transplant procedure, hospitalisation, and early follow-up. Allogeneic HSCT ranges from $60,000–$80,000, with additional costs for unrelated donor search and procurement through international registries if needed. In the United States, autologous HSCT typically costs $100,000–$200,000 and allogeneic HSCT $250,000–$400,000 or more. In the UK and Germany, costs are similarly high. Turkish centres achieve these savings while maintaining the same medical protocols, transplant infrastructure, and clinical monitoring standards as leading Western programmes.
How long does the bone marrow transplant process take, and how long must I stay in Turkey?
The full HSCT timeline from pre-transplant evaluation to safe travel home spans approximately 3–4 months. Pre-transplant evaluation and HLA typing (for allogeneic candidates) takes 1–2 weeks. Conditioning chemotherapy begins approximately one week after evaluation clearance. Hospitalisation through engraftment typically runs 4–6 weeks. After discharge, close outpatient monitoring — with blood count checks two to three times per week and frequent clinic reviews — is required for another 6–8 weeks. Most international patients should plan for a minimum stay of 60–90 days in Istanbul from the start of conditioning. Patients undergoing allogeneic transplants requiring an unrelated donor search should contact Turkare several months before the planned transplant to allow adequate time for registry searching.
What is graft-versus-host disease (GvHD) and how is it managed?
GvHD occurs when immune cells from the donor (the "graft") recognise the recipient's body tissues as foreign and mount an immune attack. Acute GvHD typically manifests within the first 100 days after transplant and can affect the skin (rash), gut (diarrhoea, nausea), and liver (elevated enzymes). Chronic GvHD can develop later and affect multiple organs over months to years. The incidence and severity of GvHD depends on HLA match quality, donor type (related versus unrelated), and conditioning intensity. Standard prophylaxis uses a combination of tacrolimus or cyclosporine with methotrexate or mycophenolate. Acute GvHD is treated with high-dose corticosteroids; refractory cases may require ruxolitinib or other second-line agents. Most mild-to-moderate cases resolve with treatment, and your Turkish transplant team will provide a detailed GvHD management protocol for your home haematologist.
What are the long-term outcomes after HSCT, and what follow-up is needed?
Long-term outcomes after HSCT depend heavily on the underlying disease, disease status at transplant, and patient factors. For multiple myeloma treated with autologous HSCT, five-year survival rates range from 50–70%. For AML in first remission treated with allogeneic HSCT, five-year survival is approximately 50–60%. Long-term risks include late infections (particularly in allogeneic patients on prolonged immunosuppression), secondary malignancies, endocrine dysfunction (thyroid disease, infertility), cardiovascular complications, and — in allogeneic recipients — chronic GvHD. Annual follow-up with a haematologist is essential, covering blood counts, immunological reconstitution assessment, organ function, vaccination updates, and cancer surveillance. Turkare provides a comprehensive medical summary for your home team before you return.
Get a written quote for this procedure
One coordinator, one price, start to finish.
